Related Experiment Video

Updated: Jun 17, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
18:46

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral

Diego A Chiappetta1, Christian Hocht, Carlos Taira

  • 1The Group of Biomaterials & Nanotechnology for Improved Medicines, Department of Pharmaceutical Technology, Faculty of Pharmacy & Biochemistry, University of Buenos Aires, 956 Junín St, 6th Floor, Buenos Aires CP1113, Argentina.

Nanomedicine (London, England)
|December 23, 2009
PubMed

Insights

Encapsulating efavirenz (EFV) in polymeric micelles significantly enhances its oral bioavailability and reduces variability in pediatric HIV treatment. This innovation aims to improve drug accessibility and affordability for children requiring anti-HIV/AIDS pharmacotherapy.

Area of Science:

  • Pharmacology
  • Materials Science
  • Nanotechnology

Background:

  • Efavirenz (EFV) is a crucial first-line anti-HIV/AIDS medication for children, but its poor aqueous solubility and limited liquid formulation availability pose challenges.
  • Current liquid formulations of EFV exhibit lower bioavailability than solid forms, hindering effective pediatric pharmacotherapy and increasing treatment costs.

Purpose of the Study:

  • To develop a novel liquid formulation of EFV by encapsulating it within polymeric micelles.
  • The primary goals are to enhance EFV's aqueous solubility and improve its oral bioavailability for pediatric use.

Main Methods:

  • Efavirenz (EFV) was incorporated into linear and branched poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles.
  • Characterization involved dynamic light scattering for size/distribution and transmission electron microscopy for morphology.
  • Oral bioavailability was assessed in Wistar rats, comparing the micellar system to EFV capsule suspension and a Miglyol 812 solution.

Main Results:

  • Polymeric micelle encapsulation significantly improved the oral bioavailability of the poorly water-soluble drug, efavirenz (EFV).
  • The micellar formulation also demonstrated a reduction in interindividual variability of drug absorption.
  • Characterization confirmed successful drug loading and micelle formation.

Conclusions:

  • Encapsulating EFV in polymeric micelles is a highly promising strategy for developing improved liquid aqueous formulations.
  • This approach holds potential for enhancing pediatric HIV pharmacotherapy, improving drug efficacy, and increasing patient access.
Abstract

More Related Videos

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...